Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Henogen |
---|---|
Information provided by: | Henogen |
ClinicalTrials.gov Identifier: | NCT00480116 |
The study vaccine has been developed for use in pre-dialysis/ haemodialysis patients and immuno-compromised individuals who could have or had a sub-optimal response following vaccination for hepatitis B with currently available commercial vaccines (target population). This study will aim to confirm in a clinical setting the consistency of production of three lots of the vaccine.
Condition | Intervention | Phase |
---|---|---|
Hepatitis B |
Biological: Adjuvanted Hepatitis B vaccine Lot 1 Biological: Adjuvanted Hepatitis B vaccine Lot 2 Biological: Adjuvanted Hep B vaccine Lot 3 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase III, Single Centre, Double Blind, Randomised Study Evaluating the Consistency of Three Lots of Henogen's New Adjuvanted Hepatitis B Vaccine, When Given at 0, 1 Month Schedule in Healthy Volunteers Aged 18 Years to 40 Years. |
Enrollment: | 450 |
Study Start Date: | January 2008 |
Study Completion Date: | April 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Biological: Adjuvanted Hepatitis B vaccine Lot 1
20 µg, IM, month 0 and 1
|
2: Active Comparator |
Biological: Adjuvanted Hepatitis B vaccine Lot 2
20µg, IM, month 0 and 1
|
3: Active Comparator |
Biological: Adjuvanted Hep B vaccine Lot 3
20µg, IM, month 0 and 1
|
Double-blind, randomised, single centre study with three groups receiving three different lots of Henogen's adjuvanted hepatitis B vaccine according to 0, 1 months schedule. Blood samples will be taken at Month 0, Months 1 and 2.
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Czech Republic | |
Vaccination and Travel Medicine Centre Poliklinika II | |
Hradec Kralove, Czech Republic, 500 03 |
Principal Investigator: | Jiri Beran, MD | Vaccination and Travel Medicine Centre Poliklinika II |
Responsible Party: | Henogen ( Houard ) |
Study ID Numbers: | HN016/HBV-002 |
Study First Received: | May 29, 2007 |
Last Updated: | August 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00480116 |
Health Authority: | Czech Republic: State Institute for Drug Control |
Consistency Immunogenicity |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases |
Hepatitis B Hepatitis, Viral, Human DNA Virus Infections Healthy |
Hepadnaviridae Infections |